{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:53:26Z","timestamp":1760122406341,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","award":["UK-110-RG-13"],"award-info":[{"award-number":["UK-110-RG-13"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ejogrb.2015.02.020","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T14:50:11Z","timestamp":1424357411000},"page":"60-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder"],"prefix":"10.1016","volume":"187","author":[{"given":"Aswini A","family":"Balachandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan RA","family":"Duckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2015.02.020_bib0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[2(2-hydroxy-2-[henylethyl)amnio]ethyl}acetanilide (YM178), a novel selective beta 3 adrenoreceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ejogrb.2015.02.020_bib0095","first-page":"935","article-title":"Mirabegron for overactive bladder: a novel, first-in-class \u03b23-agonist therapy","volume":"10","author":"Imran","year":"2013","journal-title":"Urol J"},{"issue":"1","key":"10.1016\/j.ejogrb.2015.02.020_bib0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2015.02.020_bib0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/TCRM.S33052","article-title":"New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA","volume":"9","author":"Andersson","year":"2013","journal-title":"Ther Clin Risk Manage"},{"issue":"8","key":"10.1016\/j.ejogrb.2015.02.020_bib0110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/nau.22373","article-title":"A proof-of-concept study: mirabegron, a new therapy for overactive bladder","volume":"32","author":"Chapple","year":"2013","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"10.1016\/j.ejogrb.2015.02.020_bib0115","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"issue":"4","key":"10.1016\/j.ejogrb.2015.02.020_bib0120","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejogrb.2015.02.020_bib0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenorecptor agonist, in patients with overactive bladder: results from a randomized European\u2013Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"year":"2013","series-title":"Urinary incontinence: the management of urinary incontinence in women","author":"National Institute for Health and Care Excellence","key":"10.1016\/j.ejogrb.2015.02.020_bib0130"},{"issue":"8","key":"10.1016\/j.ejogrb.2015.02.020_bib0135","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoreceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomized phase III trials and of a 1-year randomized phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejogrb.2015.02.020_bib0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3578","article-title":"Digging for data on harms in duloxetine trials","volume":"348","author":"Doshi","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2015.02.020_bib0145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, phase II studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"11","key":"10.1016\/j.ejogrb.2015.02.020_bib0150","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ejogrb.2015.02.020_bib0155","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenorecptor agonist: results from two phase I, randomized multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ejogrb.2015.02.020_bib0160","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","article-title":"Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective \u03b23-adrenoceptor agonist, after oral administration to healthy male volunteers","volume":"40","author":"Takusagawa","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejogrb.2015.02.020_bib0165","series-title":"Swanton's cardiology","first-page":"365","author":"Swanton","year":"2008"},{"issue":"6","key":"10.1016\/j.ejogrb.2015.02.020_bib0170","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/clpt.2012.181","article-title":"Proarrhythmic safety of repeat doses of mirabegron in heathly subjects: a randomized, double-blind, placebo and active-controlled thorough QT study","volume":"92","author":"Malik","year":"2012","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121151500055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121151500055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:34:09Z","timestamp":1759556049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121151500055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":17,"alternative-id":["S030121151500055X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2015.02.020","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2015.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}